Capital Markets & Financing
Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products
Triastek, Inc. ("Triastek") today announced the completion of a USD 20.4 million Pre-C financing round. This milestone marks a significant step in the advancement of Triastek's innovative solutions for drug development and manufacturing.
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT, “Intercept”), a leading biopharmaceutical company in rare and serious liver diseases, today announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash. The anticipated transaction will materially expand Alfasigma’s gastrointestinal and hepatology portfolio and its presence in the U.S. market.
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
The ADSs are expected to begin trading on the Nasdaq Global Market on September 29, 2023 under the ticker symbol “ANL”.
Wuhan YZY Biopharma – HK$176 Million IPO
Wuhan YZY Biopharma offered a total of 11,001,200 H shares, priced at $16 per H share.
United States and China launch economic and financial working groups with aim of easing tensions
The U.S. Treasury Department and China’s Ministry of Finance launched a pair of economic working groups on Friday in an effort to ease tensions and deepen ties between the nations.
Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing
The combined funds from this financing round and the company's reserves will provide ample capital to support the rapid product iteration and global development of gene-edited stem cell products by Qihan in the next four years.
Canton Biologics Completes Over 300 Million Yuan Series C Financing, Led by SDIC Venture Capital
On September 13th, Canton Biologics Co., Ltd. announced that it had recently completed a Series C financing round exceeding 300 million yuan.
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB
Following Series C1 financing on May 31, this new funding marks another step in the company's continuous growth, bringing the total amount raised in the C-round to 322 million RMB. HaoYue Capital acted as the exclusive financial advisor in this transaction.
Temasek sees ‘very attractive’ investments in China’s emerging sectors
The Singaporean state investor remains optimistic about China despite economic and geopolitical headwinds.
Bridgewater Widens Lead in China Race as Returns Outclass Rivals
Bridgewater All Weather Plus No. 2 fund up 11% through August
